Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6198335 | 0.92 | MEN1 (0.33) | MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL6199878 | 0.83 | MEN1 (0.34) | MEN1KMT2AGAACYP2C9CYP2C19 | |
| SCHEMBL6195993 | 0.81 | FAAH (0.34) | MEN1KMT2AGAACYP2C9CYP2C19 | |
| SCHEMBL6202732 | 0.80 | L3MBTL1 (0.37) | MEN1KMT2ACYP2C9CYP2C19HTR2B | |
| SCHEMBL6197611 | 0.77 | TSHR (0.34) | MEN1KMT2A | |
| SCHEMBL6196373 | 0.76 | ALDH1A1 (0.44) | MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL6196884 | 0.74 | CYP2C9 (0.37) | MEN1KMT2AGAACYP2C9CYP2C19 | |
| SCHEMBL6199298 | 0.74 | HTT (0.44) | MEN1KMT2AGAA | |
| SCHEMBL6196669 | 0.72 | L3MBTL3 (0.37) | CYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL6198867 | 0.72 | CYP2C9 (0.35) | MEN1KMT2ACYP2C9CYP2C19HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | claimed |
| EP-1140814-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2005-05-25 | — | — | EP | claimed |
| US-6878700-B1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-04-12 | — | — | US | claimed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | claimed |
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | disclosed |
| EP-1140814-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6878700-B1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-04-12 | — | — | US | disclosed |
| US-6867203-B2 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-03-15 | — | — | US | disclosed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ICAM1, VCAM1, EPCAM | MEN1 2594/4885KMT2A 4094/4885GAA 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.